A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
Condition: Crohn's Disease Interventions: Drug: upadacitinib; Other: Matching placebo for upadacitinib Sponsor: AbbVie Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials